Discovery Stems From Here
Find your tools for building human cell-based models & screening assays
Welcome to Axol Bioscience
YOUR HUMAN CELL CULTURE SPECIALISTS
Axol Bioscience, are human cell culture specialists. We provide highly validated primary cells and iPSC-derived cells from healthy donors and patients of specific disease backgrounds, together with optimized media and growth supplements. Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver robust and reliable products that our customers need to advance their research faster.
iPSC-derived atrial cardiomyocytes: a reproducible platform for translational disease insights10 September 2018
Atrial fibrillation is the most common arrhythmia observed in the clinic, affecting 6 million patients in Europe and accounting for 30% of strokes. The prevalence of atrial fibrillation continues to grow due to an aging population and is expected to double over the next 50 years. Given the need to develop safer and more effective anti-arrhythmic therapeutics, considerable efforts have been made to understand the cellular mechanisms of the disease and translate this knowledge into innovative treatments.
Improving biological tools for disease modelling and drug discovery: human iPSC-derived Atrial Cardiomyocytes5 September 2018
The rapid development of induced pluripotent stem cell-derived cells (iPSCs) is set to revolutionise modern drug discovery through the increased utilisation of human cell reagents in research.
Guest Post: Astrocytes in Rett Syndrome: why we shouldn’t ignore them?14 August 2018
Until recently, despite being the most prominent cell type in the human brain, research on astrocytes has been overshadowed by neurons. Once thought to only provide structural support to neurons it has become clear that astrocytes are a vastly heterogenous population of cells with varied functions and roles to match.
U.S. Subsidiary Scheduled23 July 2018
We are delighted to announce plans to open a new operational hub in the United States. The site will open in the fall of 2018 and will help to support Axol’s customer base in the United States and Canada.
Axol Bioscience launch Human iPSC-derived Atrial Cardiomyocytes17 July 2018
Cambridge, UK – (17th July 2018) – Axol Bioscience, the human cell culture specialists, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.